98 related articles for article (PubMed ID: 12876266)
1. Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis.
Bachus R; Neubert K; Roots I; Prudlo J; Brockmöller J; Ludolph AC
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1161. PubMed ID: 12876266
[No Abstract] [Full Text] [Related]
2. Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.
Khedhaier A; Hassen E; Bouaouina N; Gabbouj S; Ahmed SB; Chouchane L
BMC Cancer; 2008 Apr; 8():109. PubMed ID: 18423013
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer.
Brockmöller J; Kaiser R; Kerb R; Cascorbi I; Jaeger V; Roots I
Pharmacogenetics; 1996 Dec; 6(6):535-45. PubMed ID: 9014203
[TBL] [Abstract][Full Text] [Related]
4. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
6. [Genetic polymorphism of drug metabolizing enzymes].
Yokoi T; Kamataki T
Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
[No Abstract] [Full Text] [Related]
7. Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia.
Yusuf I; Djojosubroto MW; Ikawati R; Lum K; Kaneko A; Marzuki S
Adv Exp Med Biol; 2003; 531():37-46. PubMed ID: 12916779
[No Abstract] [Full Text] [Related]
8. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
9. The association of endometriosis risk and genetic polymorphisms involving dioxin detoxification enzymes: a systematic review.
Guo SW
Eur J Obstet Gynecol Reprod Biol; 2006 Feb; 124(2):134-43. PubMed ID: 16289302
[TBL] [Abstract][Full Text] [Related]
10. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
11. Genotyping metabolic polymorphisms in a cohort of Caucasians and single strand conformation polymorphism analysis of point mutations in human hprt exons 7 and 8.
Krause G; Garganta F; Kosytorz P; Scherer G
Electrophoresis; 1998 Oct; 19(14):2380-8. PubMed ID: 9820953
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro.
Marques CF; Koifman S; Koifman RJ; Boffetta P; Brennan P; Hatagima A
Oral Oncol; 2006 Jul; 42(6):632-7. PubMed ID: 16488179
[TBL] [Abstract][Full Text] [Related]
13. [Detoxication gene polymorphism and susceptibility to sporadic motor neuron disease in Russian population].
Skvortsova VI; Slominskiĭ PA; Shadrina MI; Levitskiĭ GN; Levitskaia NI; Alekhin AV; Zherebtsova AL; Serdiuk AV; Limborskaia SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):4-13. PubMed ID: 16459354
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population.
Rossini A; Rapozo DC; Soares Lima SC; Guimarães DP; Ferreira MA; Teixeira R; Kruel CD; Barros SG; Andreollo NA; Acatauassú R; Matos HJ; Albano RM; Pinto LF
Carcinogenesis; 2007 Dec; 28(12):2537-42. PubMed ID: 17916905
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping of drug metabolism in infants and children: potentials and problems.
Rane A
Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Begg EJ; Helsby NA; Jensen BP
Pharmacogenomics; 2012 Jan; 13(1):83-9. PubMed ID: 22176624
[TBL] [Abstract][Full Text] [Related]
17. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer.
Boccia S; Cadoni G; Sayed-Tabatabaei FA; Volante M; Arzani D; De Lauretis A; Cattel C; Almadori G; van Duijn CM; Paludetti G; Ricciardi G
J Cancer Res Clin Oncol; 2008 Jan; 134(1):93-100. PubMed ID: 17611777
[TBL] [Abstract][Full Text] [Related]
18. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy.
Forestiero FJ; Cecon L; Hirata MH; de Melo FF; Cardoso RF; Cerda A; Hirata RD
Clin Chim Acta; 2013 Jan; 415():215-9. PubMed ID: 23099118
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW; Commandeur JN; Vermeulen NP
Crit Rev Toxicol; 1999 Jan; 29(1):59-124. PubMed ID: 10066160
[TBL] [Abstract][Full Text] [Related]
20. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
